Expand Document  |  Expand Chapter  |  Full TOC  |  Printable HTML version
Implications of the Doha Declaration on the Trips Agreement and Public Health - Health Economics and Drugs Series No. 012
(2002; 56 pages) [French] [Spanish] View the PDF document
Table of Contents
View the documentForeword
View the documentAcknowledgements
View the documentAbbreviations and acronyms
View the documentExecutive summary
View the documentIntroduction
View the documentScope
View the documentThe role of TRIPS and IPRs
Open this folder and view contentsPublic health measures
Open this folder and view contentsFlexibility in TRIPS
Open this folder and view contentsMembers with insufficient or no manufacturing capacities
View the documentTransfer of technology to LDCs
View the documentExtension of transitional period for LDCs
View the documentSpecial treatment under TRIPS
View the documentLegal status of the Doha Declaration
View the documentIssues not covered in the Declaration
View the documentConclusions
View the documentAnnex 1 - Doha Declaration on the TRIPS Agreement and Public Health
View the documentAnnex 2 - Levels of development of pharmaceutical industry, by country
View the documentReferences
 

Annex 2 - Levels of development of pharmaceutical industry, by country

Sophisticated Pharmaceutical Industry and Research Base

Innovative Capabilities

Reproductive Capabilities - Active Ingredients and Finished Products

Reproductive Capabilities - Finished Products from Imported Ingredients only

No Pharmaceutical Industry

Belgium
France
Germany
Italy
Japan
Netherlands
Sweden
Switzerland
United
Kingdom
United States

Argentina
Australia
Austria
Canada
China
Denmark
Finland
Hungary
India
Ireland
Israel
Mexico
Portugal
Republic of Korea
Spain
USSR
Yugoslavia

Bahamas
Bolivia
Brazil
Bulgaria
Cuba
Czechoslovakia
Egypt
Indonesia
Macau, China
Norway
Poland
Puerto
Rico
Romania
Turkey

Afghanistan
Albania
Algeria
Angola
Bangladesh
Barbados
Belize
Benin
Brunei
Cambodia
Cameroon
Cape Verde
Chile
Colombia
Costa Rica
Côte d’Ivoire
Cyprus
Democratic People’s Republic of Korea
Dominican Republic
Ecuador
El Salvador
Ethiopia
Fiji
Gambia
Ghana
Greece
Guatemala
Guyana
Haiti
Honduras
Hong Kong, China
Iran (Islamic Republic of)
Iraq
Jamaica
Jordan
Kenya
Kiribati
Kuwait
Lebanon
Lesotho
Liberia
Madagascar
Malawi
Malaysia
Mali
Malta
Mauritius
Mongolia
Morocco
Mozambique
Myanmar
Namibia
Nepal
New Zealand
Nicaragua
Niger
Nigeria
Pakistan
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Saudi Arabia
Seychelles
Sierra Leone
Singapore
Solomon Islands
Somalia
South Africa
Sri Lanka
Sudan
Syrian Arab Republic
Chinese Taipei
Thailand
Tonga
Trinidad and Tobago
Tunisia
Uganda
United Arab Emirates
United Republic of Tanzania
Uruguay
Venezuela
Viet Nam
Yemen
Zaire
Zambia
Zanzibar
Zimbabwe

Andorra
Antigua and Barbuda
Aruba
Bahrain
Bermuda
Bhutan
Botswana
British Virgin Islands
Burkina Faso
Burundi
Central African
Republic
Chad
Comoros
Congo
Cook Islands
Djibouti
Dominica
Equatorial Guinea
Faeroe Islands
French Guyana
French Polynesia
Gabon
Greenland
Grenada
Guadeloupe
Guam
Guinea
Guinea-Bissau
Iceland
Laos
Libyan Arab Jamah.
Liechtenstein
Luxembourg
Maldives
Martinique
Mauritania
Mayotte
Micronesia
Nauru
Netherland Antilles
New Caledonia
Niue
Oman
Qatar
Reunion
Rwanda
St. Kitts and Nevis
St. Lucia
St. Vincent-Grenadines
Samoa
San
Marino
Sao Tome and Principe
Senegal
Suriname
Swaziland
Togo
Tuvalu
US Virgin Island
Vanuatu
Western Samoa

Source: Ballance et al, 1992.

 

to previous section
to next section
 
 
The WHO Essential Medicines and Health Products Information Portal was designed and is maintained by Human Info NGO. Last updated: June 25, 2014